Your browser doesn't support javascript.
loading
Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice.
Xin, Bing; Yang, Meixiang; Wu, Panyisha; Du, Li; Deng, Xingyu; Hui, Enfu; Feng, Gen-Sheng.
Afiliação
  • Xin B; Department of Pathology, Division of Biological Sciences and Moores Cancer Center, University of California at San Diego, La Jolla, California, USA.
  • Yang M; Department of Pathology, Division of Biological Sciences and Moores Cancer Center, University of California at San Diego, La Jolla, California, USA.
  • Wu P; Department of Pathology, Division of Biological Sciences and Moores Cancer Center, University of California at San Diego, La Jolla, California, USA.
  • Du L; Department of Pathology, Division of Biological Sciences and Moores Cancer Center, University of California at San Diego, La Jolla, California, USA.
  • Deng X; Department of Pathology, Division of Biological Sciences and Moores Cancer Center, University of California at San Diego, La Jolla, California, USA.
  • Hui E; Section of Cell & Developmental Biology, Division of Biological Sciences, University of California at San Diego, La Jolla, California, USA.
  • Feng GS; Department of Pathology, Division of Biological Sciences and Moores Cancer Center, University of California at San Diego, La Jolla, California, USA.
Hepatology ; 76(3): 630-645, 2022 09.
Article em En | MEDLINE | ID: mdl-34860431

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígeno B7-H1 / Neoplasias Hepáticas Limite: Animals Idioma: En Revista: Hepatology Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígeno B7-H1 / Neoplasias Hepáticas Limite: Animals Idioma: En Revista: Hepatology Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
...